| Aug 14 |
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
|
| Aug 12 |
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
|
| Aug 8 |
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
|
| Jul 30 |
EVAX: Initiating Coverage of Evaxion
|
| Jul 16 |
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
|
| Jul 3 |
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
|
| Jun 26 |
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
|
| Jun 17 |
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
|
| Jun 13 |
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
|
| Jun 3 |
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
|
